Last updated on June 2018

A clinical trial sponsored by Bayer for a research study of Neladenoson bialanate (BAY1067197), Placebo

Brief description of study

The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.

Clinical Study Identifier: NCT03098979

Contact Investigators or Research Sites near you

Start Over

Shonan Fujisawa Tokushukai Hospital
Fujisawa, Japan